Aspira pathlab & Diagnostics Limited has officially set March 27, 2026 as the record date for its upcoming open offer under SEBI takeover regulations. The announcement was made by Aftertrade Broking Private Limited, the manager for the open offer, in compliance with Securities and Exchange Board of India regulations.

Open Offer Details

The open offer encompasses significant parameters for public shareholders of the target company:

Acquirer Information

The open offer involves five primary acquirers working collectively to acquire the stake in Aspira Pathlab & Diagnostics Limited. The acquirer group includes Mr. Arvind Karsandas Bhanushali, Mrs. Deepali Arvind Bhanushali, Mr. Jay Arvind Bhanushali, Mr. Nikunj Velji Mange, and Mr. Raj Arvind Bhanushali. Additionally, Mrs. Shraddha Nikunj Mange is participating as a Person Acting in Concert (PAC) with the acquirers.

Regulatory Timeline

The open offer process has followed a structured timeline in accordance with SEBI regulations:

• Public Announcement: September 26, 2025
• Detailed Public Statement: Published in newspapers on October 6, 2025
• Draft Letter of Offer: October 13, 2025
• Record Date Announcement: March 25, 2026
• Identified Record Date: March 27, 2026

Management and Compliance

Aftertrade Broking Private Limited, registered with SEBI under registration number INM000013110, is serving as the manager for this open offer. The company has confirmed that the March 27, 2026 date will determine the names of shareholders who will receive the Letter of Offer. This compliance measure aligns with regulation 18(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

The announcement was signed by Vanesh Panchal, Director of Aftertrade Broking Private Limited, with DIN 06944544, ensuring proper authorization and regulatory compliance for the open offer process.

Aspira pathlab & Diagnostics Limited has announced the resignation of its Company Secretary cum Compliance Officer, marking a significant change in the company's key managerial personnel. The announcement was made through a formal disclosure to BSE Limited on March 07, 2026, in compliance with regulatory requirements.

Key Personnel Change Details

Ms. Krupali Shah, holding Membership No: A70473, has tendered her resignation from the position of Company Secretary cum Compliance Officer due to personal reasons. The resignation has been accepted by the company's Board of Directors and will become effective from March 08, 2026.

Regulatory Compliance

The company has fulfilled its disclosure obligations pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was made to BSE Limited, where the company's shares are listed under Security Code 540788 and Security ID ASPIRA.

In her formal resignation letter to the Board of Directors, Ms. Shah expressed gratitude for the support and cooperation extended during her tenure with the company. She specifically confirmed that there are no other material reasons for her resignation beyond those mentioned in her letter.

Administrative Formalities

The resignation letter was received and accepted by the company, with Executive Director Nikunj Mange signing the acceptance on behalf of Aspira Pathlab & Diagnostics Limited. Ms. Shah has requested the company to file necessary forms with the Registrar of Companies, Ministry of Corporate Affairs to formalize her resignation.

The company's disclosure follows the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, ensuring complete transparency regarding changes in key managerial personnel. This resignation represents a routine corporate governance matter handled in accordance with established regulatory frameworks.